MyFinsight
Home
Blog
About
Contact
something is missing
$16,714,041
Employee-related costs
$9,148,153
Non-program expenses
$3,207,656
Stock-based compensation
expense
$3,036,615
Program expenses-Other
Programs
$2,074,128
Other segment items
$695,777
Depreciation and
amortization
$167,226
Net loss
$30,983,993
Accounts payable
$384,635
Lease liabilities
$152,307
Canceled cashflow
$4,059,603
Net cash used in
operating activities
$17,070,553
Canceled cashflow
$14,450,382
Program
expenses-Atebimetinib IMM1104
-$4,055,258
Program
expenses-Envometinib IMM6415
-$4,345
Net decrease in cash
and cash...
-$272,741,816
Canceled cashflow
$17,070,553
Maturities of marketable
securities
$9,000,000
Accrued expenses
-$6,687,037
Prepaid expenses and
other current assets
$3,085,087
Stock-based compensation
expense
-$3,036,615
Other assets
$797,414
Net accretion of
discount on marketable...
$404,723
Depreciation and
amortization expense
-$167,226
Reduction in carrying
amount of right-of-use...
-$163,900
Other liabilities
-$93,747
Intangible asset
amortization
-$14,633
Net cash provided by
financing activities
-$226,759,910
Net cash used in
investing activities
-$63,052,459
Canceled cashflow
$9,000,000
something is missing
-$211,360,014
Proceeds from issuance of
common stock under...
-$15,020,046
Proceeds from issuance of
common stock under...
-$251,585
Proceeds from exercise of
stock options
-$128,265
Purchases of marketable
securities
$71,990,845
Purchases of property and
equipment
$61,614
Back
Back
Cash Flow
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)
source: myfinsight.com